MEPHENTERMINE SULFATE

/static/temp/default.svg

Search structure


Trade Names	WYAMINE SULFATE
Synonyms	Mephentermine sulfate Mephentermine sulfate dihydrate Mephentermine sulphate Mephine NSC-758424 Wyamine Wyamine sulfate Wyamine sulphate
Status
Molecule Category	Salt-form
UNII	580655Z8RR
EPA CompTox	DTXSID1047780


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DNKCFBJMFIUNRS-UHFFFAOYSA-N
Smiles	CNC(C)(C)Cc1ccccc1.CNC(C)(C)Cc1ccccc1.O=S(=O)(O)O
InChI	InChI=1S/2C11H17N.H2O4S/c21-11(2,12-3)9-10-7-5-4-6-8-10;1-5(2,3)4/h24-8,12H,9H2,1-3H3;(H2,1,2,3,4)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C22H36N2O4S
Molecular Weight	424.61
AlogP	2.23
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	12.03
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	12.0

Bioactivity

Mechanism of Action	Action	Reference
Adrenergic receptor agonist	AGONIST	PubMed

Assay Description	Organism	Bioactivity	Reference
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-4.77 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	13.53 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.16 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.16 %

Cross References

Resources	Reference
ChEBI	6756
ChEMBL	CHEMBL3184799
FDA SRS	580655Z8RR
Guide to Pharmacology	7222
KEGG	C07889
PubChem	71611
SureChEMBL	SCHEMBL121177
ZINC	ZINC08132748

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).